Tag Archives: R&D

Fred Hassan: More Musings on the Biopharma Learning Curve

Hindsight can be a great teacher – but only if you have the self-awareness needed to adapt those learnings to the next business challenge, whose rough edges are by definition almost always “non-recurring.” In other words, because the circumstances of any setback are unique, the astute manager knows that recovery depends on recognizing that the […]
Posted in healthcare, leadership, People, R&D, Sales, Strategy | Also tagged , , , , | 2 Comments

Big Pharma's Second Life

Can big pharma solve its fixed cost problem by going virtual? Not entirely, but drug companies can get more out of their CRO partners by treating them less like avatars and more like equals, according to conference-goers at a CBI event in The Triangle. The problem with overbearing project mangers on the sponsor side of […]
Posted in Biotech, People, R&D, Strategy, Supply Chain | Also tagged , , , , | Leave a comment

Woodcock Urges Forward March Toward Personalized Medicine

New approaches for conducting clinical trials and developing therapies that actually prevent and cure disease are key to the future of effective drug therapy, according to Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research (CDER). Personalized medicine has achieved mainstream status, accounting for more new drug approvals and promising pipeline candidates, […]
Posted in Technology | Also tagged , , , , , , , , , , | Leave a comment

Global Biosimilars Market to Reach $2.4 Billion in 2013

By Adeline Siew, Editor, Pharmaceutical Technology Europe. The global market for biosimilar drugs has been forecasted to be worth $2.445 billion this year, according to a new report by British market research specialist Visiongain. The growth represents a 20% increase from last year and accounts for approximately 2% of the overall biologics market. Moreover, the […]
Posted in Biotech, Global, Guest Blog, R&D | Also tagged , , | Leave a comment

Tough Times Ahead for New Medicines under NHS England?

By Leela Barham You’d be forgiven for missing it with the vast array of new agencies and the policy documents, guidance, consultations and ‘engagement’ activity they’re doing on in the ‘new’ NHS in England, but on the 4th April NHS England (formerly the NHS Commissioning Board) set out 15 commissioning policies in 250 pages.  They’re […]
Posted in Europe, Global, Guest Blog, healthcare, pricing | Also tagged , , , , | Leave a comment
  • Categories

  • Meta